SAN FRANCISCO, USA, SUZHOU, China, July 26, 2024/PRNewswire/ -- As the global population ages and chronic diseases increase, the need for new drug development is becoming increasingly urgent. Traditional drug development processes take a long time and are expensive. The introduction of AI technology has provided a new solution to this problem. Cinda Biotech has always been committed to promoting industry development through scientific and technological innovation. Recently, Cinda Biotech and Weixin Computing reached a cooperation to jointly promote the construction and improvement of the Cinda Biotech National Clearing House computing platform. Through this cooperation, the two sides will integrate their superior resources and technologies and use AI technology to further accelerate the drug development process.
As an important R&D engine for Cinda Biotech, the Cinda Guoqing Institute thoroughly explores and actively lays out AI drug research and development. In this cooperation, Cinda Biotech will use Weixin Computing's WeMol platform to build and improve the National Qingyuan computing platform to accelerate its drug development process. By building an efficient, easy-to-use, digital, intelligent, and automated one-stop AI drug development platform, Cinda Biotech hopes to reduce AI implementation costs and experimental costs, shorten the drug development cycle, improve the R&D success rate, and bring more innovative drugs and treatment plans to patients.
He Kaijie, vice president of tumor biology and ADC drug research at Cinda Biopharmaceutical Group, said, “AI is injecting new momentum into the global pharmaceutical and biotechnology industry. We are very excited to further enhance our R&D capabilities and accelerate the discovery and development of innovative drugs by using the most advanced AI technology. We look forward to making greater breakthroughs in the global pharmaceutical market in the future with strong technical support.”
About Trustworthy Computing
Weixin Computing (Wecomput) is committed to “computational technology-driven innovative drug research and development”. Based on a deep understanding of the innovative drug development process, it integrates artificial intelligence, biophysics, high-performance computing and other technologies to create a unique digital, intelligent, and automated drug molecule generation, design and simulation platform, which is expected to revolutionize traditional drug discovery methods and drive the development process of innovative drugs such as antibodies, proteins, small molecules, and mRNAs. The parent company, Beijing Zhongda Weixin Technology Co., Ltd. was incorporated in 2015 and was selected as a national high-tech enterprise. It received equity investment from Sequoia Capital in 2021, and was selected as a senior member of the NVIDIA Inception Program. Up to now, Wecomput has served hundreds of customers at home and abroad, covering many biomedical companies, universities, hospitals, scientific research institutions, and has independently developed WeMoL, a leading pharmaceutical molecular design and intelligent calculation platform.
About Cinda Biotech
“Beginning with faith, achieving action” is the mission and goal of Cinda Biotech to develop high-quality biopharmaceuticals that ordinary people can use. Founded in 2011, Cinda Biotech is committed to developing, producing and selling innovative drugs in major diseases such as oncology, autoimmunity, metabolism, and ophthalmology, so that our work can benefit more lives. The company has been approved for marketing of 10 products, namely Cindilizumab injection (daberzumab), bevacizumab injection (Dayou same), adalimumab injection (sulixin), rituximab injection (dabroximab), pemitinib tablets (dabbotan), olebatinib tablets (Nellicol), ramosilumab injections (siranzal), cefotinib capsules (retuo), iquiolene injections (folisol) and tolesu Cizumab injection (Cipilac). Currently, there are also 4 varieties in the NMPA review. 4 new drug molecules have entered phase III or key clinical research, and 18 new drug types have entered clinical research. The company has reached more than 30 strategic partnerships with international partners such as Eli Lilly, Roche, Sanofi, Adimab, Incyte, and MD Anderson Cancer Center.
While continuously developing innovative drugs and seeking its own development, Cinda Biotech adheres to the people-centered development philosophy of economic construction. Over the years, we have always been scientific and kind, adhering to the “patient-centered” approach, caring for patients and their families, and actively fulfilling social responsibilities. The company has successively initiated and participated in a number of drug charity aid projects, so that more and more patients can benefit from advances in life science and can buy and use high-quality biopharmaceuticals. Up to now, the Cinda Biotech Patient Assistance Program has benefited more than 170,000 ordinary patients, and the total value of drug donations is RMB 3.4 billion. Cinda Biotech hopes to work with everyone to raise the level of development of China's biopharmaceutical industry to meet people's accessibility to medicine and people's pursuit of a better life, health, and beauty.
For details, please visit the company website: or the company's LinkedIn account: Innovent Biologics.
Disclaimer: Innovent does not recommend the use of unapproved drugs/indications.
*Remocizumab injection (Shiranze) and ceptinib capsules (Ruituo) were developed by Eli Lilly.